Registry of Patients Having Received oNKord®

Recruiting now

Conditions studied: AML

In brief

ReKORD is an observational study (Registry) enrolling participants who have received at least one dose of oNKord® (allogeneic ex vivo-generated Natural Killer \[NK\] cells from CD34+ umbilical cord blood progenitor cells) in a clinical trial. Participants from multiple previous clinical trials of oNKord® can be enrolled in this Registry.

Key facts

Study ID

NCT05290662

Run by

Glycostem Therapeutics BV

People needed

50

Starts

2022-06-14

Expected to finish

2028-03-01

Last updated by the study team

2022-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Receipt of at least one dose of oNKord® in a clinical trial
• Participation must be within 3 years after the first infusion of oNKord®
• Signature of ICF

You may not qualify if…

• N/A

Where it is running

• Medizinische Hochschule Hannover — Hanover, Germany (enrolling)
• University Hospital Basel — Basel, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.